The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


REVAXIS Suspension for injection in pre-filled syringe Diphtheria, tetanus and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content)



Sanofi PasteurPA2131/007/001

Main Information

Trade NameREVAXIS Suspension for injection in pre-filled syringe Diphtheria, tetanus and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content)
Active SubstancesDiphtheria toxoid
Tetanus toxoid
POLIOVIRUS, TYPE 1
Poliovirus, type 2
Poliovirus, type 3
Dosage FormSuspension for injection in pre-filled syringe
Licence HolderSanofi Pasteur
Licence NumberPA2131/007/001

Group Information

ATC CodeJ07CA01 diphtheria-poliomyelitis-tetanus

Status

License statusAuthorised
Licence Issued18/02/2000
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back